发明名称 Uses of DGAT1 inhibitors
摘要 The present invention relates to the use of a DGAT1 inhibitor, or a pharmaceutically acceptable salt or ester thereof, for the prevention, delay of progression or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia. The present invention further relates to the use of a pharmaceutical composition comprising a DGAT1 inhibitor, or a pharmaceutically acceptable salt or ester thereof, for the prevention, delay of progression or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia.
申请公布号 US9061012(B2) 申请公布日期 2015.06.23
申请号 US201113637372 申请日期 2011.03.29
申请人 Novartis AG 发明人 Meyers Charles;Serrano-Wu Michael H.;Thuren Tom
分类号 A61K31/44;A61K31/42 主分类号 A61K31/44
代理机构 代理人 Lynch James L.
主权项 1. A method for the delay of progression or treatment of chylomicronemia due to familial chylomicronemia syndrome comprising administration of a therapeutically effective amount of the DGAT1 inhibitor trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl]cyclohexane acetic acid, or a pharmaceutically acceptable salt or ester thereof, to a human subject in need of such treatment.
地址 Basel CH